Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma

British Journal of Cancer

Volumn 105, Issue 1, 2011, Pages 131-138

  Miyamoto, M ^a,b   Ojima, H ^a   Iwasaki, M ^c   Shimizu, H ^a   Kokubu, A ^a   Hiraoka, N ^a   Kosuge, T ^d   Yoshikawa, D ^b   Kono, T ^b   Furukawa, H ^b   Shibata, T ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b ASAHIKAWA MEDICAL COLLEGE   (Japan)

^c NATIONAL CANCER CENTER   (Japan)

^d NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

c Met; cholangiocarcinoma; epidermal growth factor receptor; immunohistochemistry; prognostic factor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; SCATTER FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; FEMALE; HEALTH SURVEY; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; BILE DUCT NEOPLASMS; BILE DUCTS, EXTRAHEPATIC; BILE DUCTS, INTRAHEPATIC; BLOTTING, WESTERN; CHOLANGIOCARCINOMA; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL RATE;

EID: 79959731074     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.199     Document Type: Article

References (42)

1. Aishima SI, Taguchi KI, Sugimachi K, Shimada M, Sugimachi K, Tsuneyoshi M (2002) c-erbB-2 and c-Met expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangio-carcinoma. Histopathology 40: 269-278 (Pubitemid 34227118)
2. Aljiffry M, Abdulelah A, Walsh M, Peltekian K, Alwayn I, Molinari M (2009) Evidence-based approach to cholangiocarcinoma: a systematic review of the current literature. J Am Coll Surg 208: 134-147
3. Bergstrom JD, Westermark B, Heldin NE (2000) Epidermal growth factor receptor signaling activates met in human anaplastic thyroid carcinoma cells. Exp Cell Res 259: 293-299
4. Blechacz B, Gores GJ (2008) Cholangiocarcinoma: advances in patho-genesis, diagnosis, and treatment. Hepatology 48: 308-321 (Pubitemid 351975555)
5. Boix L, Rosa JL, Ventura F, Castells A, Bruix J, Rodes J, Bartrons R (1994) c-met mRNA overexpression in human hepatocellular carcinoma. Hepatology 19: 88-91 (Pubitemid 24020476)
6. Dempke WC, Heinemann V (2009) Resistance to EGF-R (erbB-1) and VEGF-R modulating agents. Eur J Cancer 45: 1117-1128
7. Drebber U, Baldus SE, Nolden B, Grass G, Bollschweiler E, Dienes HP, Holscher AH, Monig SP (2008) The overexpression of c-met as a prognostic indicator for gastric carcinoma compared to p53 and p21 nuclear accumulation. Oncol Rep 19: 1477-1483
8. Eder JP, Vande WGF, Boerner SA, LoRusso PM (2009) Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res 15: 2207-2214
9. Farazi PA, Zeisberg M, Glickman J, Zhang Y, Kalluri R, DePinho RA (2006) Chronic bile duct injury associated with fibrotic matrix microenviron-ment provokes cholangiocarcinoma in p53-deficient mice. Cancer Res 66: 6622-6627 (Pubitemid 44085618)
10. Furge KA, Zhang YW, Vande WGF (2000) Met receptor tyrosine kinase: enhanced signaling through adapter proteins. Oncogene 19: 5582-5589
11. Garcia S, Dales JP, Charafe Jauffret E, Carpentier Meunier S, Andrac Meyer L, Jacquemier J, Andonian C, Lavaut MN, Allasia C, Bonnier P, Charpin C (2007) Overexpression of c-Met and of the transducers PI3K, FAK and JAK in breast carcinomas correlates with shorter survival and neoangiogenesis. Int J Oncol 31: 49-58
12. Gentile A, Trusolino L, Comoglio PM (2008) The Met tyrosine kinase receptor in development and cancer. Cancer Metastasis Rev 27: 85-94
13. Guo A, Villen J, Kornhauser J, Lee KA, Stokes MP, Rikova K, Possemato A, Nardone J, Innocenti G, Wetzel R, Wang Y, MacNeill J, Mitchell J, Gygi SP, Rush J, Polakiewicz RD, Comb MJ (2008) Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl Acad Sci USA 105: 692-697 (Pubitemid 351171770)
14. Hamilton SR, Altonen LA (2000) World Health Organization Classification of Tumours: pathology & Genetics: Tumours of the Digestive System. IARC Press: Lyon
15. Herrera LJ, El Hefnawy T, Queiroz OPE, Raja S, Finkelstein S, Gooding W, Luketich JD, Godfrey TE, Hughes SJ (2005) The HGF receptor c-Met is overexpressed in esophageal adenocarcinoma. Neoplasia 7: 75-84 (Pubitemid 40209473)
16. Hezel AF, Zhu AX (2008) Systemic therapy for biliary tract cancers. Oncologist 13: 415-423 (Pubitemid 351679921)
17. Hida Y, Morita T, Fujita M, Miyasaka Y, Horita S, Fujioka Y, Nagashima K, Katoh H (1999) Clinical significance of hepatocyte growth factor and c-Met expression in extrahepatic biliary tract cancers. Oncol Rep 6: 1051-1056
18. Ji J, Zhao P, Huang B (2008) [Study of gastric carcinoma and PCNA and c-met gene abnormality]. Wei Sheng Yan Jiu 37: 479-482
19. Jo M, Stolz DB, Esplen JE, Dorko K, Michalopoulos GK, Strom SC (2000) Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells. J Biol Chem 275: 8806-8811 (Pubitemid 30180235)
20. Kong DS, Song SY, Kim DH, Joo KM, Yoo JS, Koh JS, Dong SM, Suh YL, Lee JI, Park K, Kim JH, Nam DH (2009) Prognostic significance of c-Met expression in glioblastomas. Cancer 115: 140-148
21. Liu C, Park M, Tsao MS (1992) Overexpression of c-met proto-oncogene but not epidermal growth factor receptor or c-erbB-2 in primary human colorectal carcinomas. Oncogene 7: 181-185
22. Lutterbach B, Zeng Q, Davis LJ, Hatch H, Hang G, Kohl NE, Gibbs JB, Pan BS (2007) Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival. Cancer Res 67: 2081-2088 (Pubitemid 46424226)
23. Mouzas IA, Dimoulios P, Vlachonikolis IG, Skordilis P, Zoras O, Kouroumalis E (2002) Increasing incidence of cholangiocarcinoma in Crete 1992-2000. Anticancer Res 22: 3637-3641 (Pubitemid 36132842)
24. Nakamura Y, Niki T, Goto A, Morikawa T, Miyazawa K, Nakajima J, Fukayama M (2007) c-Met activation in lung adenocarcinoma tissues: an immunohistochemical analysis. Cancer Sci 98: 1006-1013 (Pubitemid 46865384)
25. Nakazawa K, Dobashi Y, Suzuki S, Fujii H, Takeda Y, Ooi A (2005) Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers. J Pathol 206: 356-365 (Pubitemid 40903200)
26. Ojima H, Yoshikawa D, Ino Y, Shimizu H, Miyamoto M, Kokubu A, Hiraoka N, Morofuji N, Kondo T, Onaya H, Okusaka T, Shimada K, Sakamoto Y, Esaki M, Nara S, Kosuge T, Hirohashi S, Kanai Y, Shibata T (2010) Establishment of six new human biliary tract carcinoma cell lines and identification of MAGEH1 as a candidate biomarker for predicting the efficacy of gemcitabine treatment. Cancer Sci 101: 882-888
27. Okuda K, Nakanuma Y, Miyazaki M (2002) Cholangiocarcinoma: recent progress. Part 1: epidemiology and etiology. J Gastroenterol Hepatol 17: 1049-1055 (Pubitemid 35013958)
28. Peghini PL, Iwamoto M, Raffeld M, Chen YJ, Goebel SU, Serrano J, Jensen RT (2002) Overexpression of epidermal growth factor and hepatocyte growth factor receptors in a proportion of gastrinomas correlates with aggressive growth and lower curability. Clin Cancer Res 8: 2273-2285 (Pubitemid 34753601)
29. Reznik TE, Sang Y, Ma Y, Abounader R, Rosen EM, Xia S, Laterra J (2008) Transcription-dependent epidermal growth factor receptor activation by hepatocyte growth factor. Mol Cancer Res 6: 139-150 (Pubitemid 351378174)
30. Sawada K, Radjabi AR, Shinomiya N, Kistner E, Kenny H, Becker AR, Turkyilmaz MA, Salgia R, Yamada SD, Vande WGF, Tretiakova MS, Lengyel E (2007) c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res 67: 1670-1679 (Pubitemid 46383393)
31. Smolen GA, Sordella R, Muir B, Mohapatra G, Barmettler A, Archibald H, Kim WJ, Okimoto RA, Bell DW, Sgroi DC, Christensen JG, Settleman J, Haber DA (2006) Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci USA 103: 2316-2321 (Pubitemid 43271667)
32. Sobin LH, Wittekind CH (2002) TNM Classification of Malignant Tumours, 6th edn. Wiley-Liss/International Union Against Cancer (UICC): New York
33. Socoteanu MP, Mott F, Alpini G, Frankel AE (2008) c-Met targeted therapy of cholangiocarcinoma. World J Gastroenterol 14: 2990-2994
34. Suzuki K, Hayashi N, Yamada Y, Yoshihara H, Miyamoto Y, Ito Y, Ito T, Katayama K, Sasaki Y, Ito A et al (1994) Expression of the c-met protooncogene in human hepatocellular carcinoma. Hepatology 20: 1231-1236 (Pubitemid 24323571)
35. Terada T, Nakanuma Y, Sirica AE (1998) Immunohistochemical demonstration of MET overexpression in human intrahepatic cholangiocarci-noma and in hepatolithiasis. Hum Pathol 29: 175-180 (Pubitemid 28099514)
36. Toschi L, Janne PA (2008) Single-agent and combination therapeutic strategies to inhibit hepatocyte growth factor/MET signaling in cancer. Clin Cancer Res 14: 5941-5946
37. Weidner KM, Sachs M, Birchmeier W (1993) The Met receptor tyrosine kinase transduces motility, proliferation, and morphogenic signals of scatter factor/hepatocyte growth factor in epithelial cells. J Cell Biol 121: 145-154 (Pubitemid 23097370)
38. Weinberger PM, Yu Z, Kowalski D, Joe J, Manger P, Psyrri A, Sasaki CT (2005) Differential expression of epidermal growth factor receptor, c-Met, and HER2/neu in chordoma compared with 17 other malignancies. Arch Otolaryngol Head Neck Surg 131: 707-711 (Pubitemid 41186892)
39. Yachimski P, Pratt DS (2008) Cholangiocarcinoma: natural history, treatment, and strategies for surveillance in high-risk patients. J Clin Gastroenterol 42: 178-190
40. Yoshikawa D, Ojima H, Iwasaki M, Hiraoka N, Kosuge T, Kasai S, Hirohashi S, Shibata T (2008) Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcino-ma. Br J Cancer 98: 418-425 (Pubitemid 351161240)
41. Yoshikawa D, Ojima H, Kokubu A, Ochiya T, Kasai S, Hirohashi S, Shibata T (2009) Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarci-noma. Br J Cancer 100: 1257-1266
42. Zhang YW, Su Y, Volpert OV, Vande WGF (2003) Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. Proc Natl Acad Sci USA 100: 12718-12723 (Pubitemid 37339965)